765 related articles for article (PubMed ID: 25682093)
21. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
22. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
Bady P; Delorenzi M; Hegi ME
J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
[TBL] [Abstract][Full Text] [Related]
24. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
[TBL] [Abstract][Full Text] [Related]
25. Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
Petrova EI; Galstyan SA; Telysheva EN; Ryzhova MV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):52-58. PubMed ID: 38054227
[TBL] [Abstract][Full Text] [Related]
26. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
28. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF
BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941
[TBL] [Abstract][Full Text] [Related]
29. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
Gömöri E; Pál J; Kovács B; Dóczi T
Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
31. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
Mulholland S; Pearson DM; Hamoudi RA; Malley DS; Smith CM; Weaver JM; Jones DT; Kocialkowski S; Bäcklund LM; Collins VP; Ichimura K
Int J Cancer; 2012 Sep; 131(5):1104-13. PubMed ID: 22020830
[TBL] [Abstract][Full Text] [Related]
32. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
[TBL] [Abstract][Full Text] [Related]
33. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
34. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
35. Sensitive Detection and Conjoint Analysis of Promoter Methylation by Conjugated Polymers for Differential Diagnosis and Prognosis of Glioma.
Ma L; Huang Y; Zhang H; Ning W; Qi R; Yuan H; Lv F; Liu L; Yu C; Wang S
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9291-9299. PubMed ID: 32436715
[TBL] [Abstract][Full Text] [Related]
36. The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Wei KC; Chen CY; Feng LY; Huang WT; Chen CH; Hsu PW; Wang K; Hood LE; Chen LY
PLoS One; 2017; 12(6):e0178842. PubMed ID: 28575062
[TBL] [Abstract][Full Text] [Related]
37. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Everhard S; Tost J; El Abdalaoui H; Crinière E; Busato F; Marie Y; Gut IG; Sanson M; Mokhtari K; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Thillet J
Neuro Oncol; 2009 Aug; 11(4):348-56. PubMed ID: 19224763
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Ochsenbein AF; Schubert AD; Vassella E; Mariani L
J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
[TBL] [Abstract][Full Text] [Related]
39. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
40. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
